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Abstract 
 
The role of vitamin D in curtailing the development of obesity and comorbidities like the metabolic 
syndrome (MetS) and type-2 diabetes has received much attention recently. However, clinical trials 
have failed to conclusively demonstrate the benefits of vitamin D supplementation. In most studies, 
serum 25-hydroxyvitamin D (25(OH)D) decreases with increasing BMI above normal weight. 
These low 25(OH)D levels may also be a proxy for reduced exposure to sunlight-derived ultraviolet 
radiation (UVR). Here we investigate whether UVR and/or vitamin D supplementation modifies the 
development of obesity and type-2 diabetes in a murine model of obesity. Chronic sub-erythemal 
and erythemal UVR significantly suppressed weight gain, glucose intolerance, insulin resistance, 
non-alcoholic fatty-liver disease measures and serum levels of fasting insulin, glucose and 
cholesterol in C57Bl/6 male mice fed a high fat diet. However, many of the benefits of UVR were 
not reproduced by vitamin D supplementation. In further mechanistic studies, skin induction of the 
UVR-induced mediator, nitric oxide reproduced many of the effects of UVR. These studies suggest 
that UVR (sunlight exposure) may be an effective means of suppressing the development of obesity 
and MetS, through mechanisms that are independent of vitamin D but dependent on other UVR-
induced mediators like nitric oxide. 
   4 
Introduction 
 
Obesity has significant effects on our  health and wellbeing: obese people have increased co-
morbidities resulting from cardiovascular disease, type-2 diabetes, breast and colon cancers, 
dementia and depression. Vitamin D deficiency is recognized as a health problem affecting many 
individuals worldwide (1) and may contribute toward the development of obesity. Insufficient levels 
of vitamin D are associated with obesity, and obese people are more likely than others to be vitamin D 
deficient  (reviewed in  (2;  3)).  Vitamin D is synthesised from dermal  7-dehydrocholesterol after 
cutaneous exposure to the ultraviolet radiation (UVR) of sunlight. Vitamin D is transported to the liver 
bound to the vitamin D-binding protein for conversion into the storage form, 25-hydroxyvitamin D 
(25(OH)D), before further conversion into the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D) in 
the kidneys. Many cells in other tissues express the enzymatic machinery required to convert 25(OH)D 
into active 1,25(OH)2D (2).  
 
It is not known whether vitamin D deficiency is a causal pathway for the development of obesity and 
the metabolic syndrome (MetS). Serum 25(OH)D levels generally decrease with increasing BMI 
above normal weight (4) and results from a genetic association study suggest that higher BMI leads to 
reduced circulating 25(OH)D levels  (5).  Furthermore, randomized controlled trials that test the 
efficacy of vitamin D supplementation for weight loss (2) or curbing MetS-related diseases like type-2 
diabetes and cardiovascular disease (3; 6; 7) have had little success. Even so, there is currently much 
interest in vitamin D supplementation as a clinical means of controlling obesity and MetS, with 
>100 clinical trials underway assessing vitamin D supplementation (ClinicalTrials.gov).  
 
Increased storage of fat-soluble vitamin D in obese individuals may reduce circulating 25(OH)D 
(8). Also, obese people exercise less and spend less time in the sun (9). Our increasingly ‘indoor’ 
lifestyles, coupled with concerns about rising skin cancer rates for light-skinned populations, have   5 
resulted in concomitant decreases in sun exposure (10) and increased prevalence of vitamin D 
deficiency  (11)  worldwide  including  countries like Australia, which experiences  some of the 
highest obesity rates in the world. Chronic sunlight exposure (particularly sub-erythemal UVR) 
itself may be beneficial for obesity and MetS outcomes like type-2 diabetes (12) and non-alcoholic 
fatty liver disease (NAFLD) (13).  
 
In this paper, we present data further defining the role of sunlight-induced vitamin D in modulating 
the development of obesity and aberrant metabolic outputs including glucose intolerance, insulin 
resistance, and NAFLD. We directly compared the abilities of chronic UVR and/or dietary vitamin 
D to alter the development of obesity using a physiologically relevant model induced by feeding 
C57Bl/6 male mice a high fat diet. Our previous studies have shown that chronic UVR does not 
modify serum 25(OH)D in male mice (14),  allowing  us to investigate the ability of UVR to 
modulate obesity and MetS independently of circulating 25(OH)D. Here, chronic UVR but not 
dietary vitamin D suppressed weight gain and various measures of MetS (circulating cholesterol 
levels, glucose intolerance, insulin resistance).  Further,  while vitamin D supplementation did 
improve NAFLD,  UVR suppressed its development even more effectively.  Vitamin D 
supplementation suppressed circulating TNFα levels, identifying a possible mechanism for control 
of NAFLD. In further mechanistic studies, UVR-induced nitric oxide (NO) significantly suppressed 
some measures of obesity and MetS development, including weight, white adipose tissue (WAT) 
accumulation, fasting glucose, the development of insulin resistance and NAFLD. These studies 
suggest that while vitamin D supplementation may be useful for preventing NAFLD development, 
sunlight exposure may be more effective, and have the added benefits of suppressing obesity and 
MetS through NO-dependent pathways. 
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Research Design and Methods 
 
Mice. All experiments were performed according to the ethical guidelines of the National Health 
and Medical Research Council of Australia and with approval from the Telethon Institute for Child 
Health Research Animal Ethics Committee. C57Bl/6 male mice were purchased from the Animal 
Resources Centre, Western Australia. The temperature and lighting were controlled, with a normal 
12-hour light/dark cycle to mimic day and night. Mice were housed under perspex-filtered 
fluorescent lighting, which emitted no detectable ultraviolet (UV) B radiation as measured using a 
UV radiometer (UVX Digital Radiometer, Ultraviolet Products Inc., Upland, CA, USA). Mice were 
allowed access to food and acidified water ad libitum.  
 
Diet. All diets were obtained from Specialty Feeds (Glen Forrest, Western Australia) and included 
two semi-pure low fat diets (5% fat; canola oil), which were supplemented (LF-D
+) or not (LF-D
-) 
with vitamin D3 (2280 or 0 IU vitamin D3/kg) and two high fat diets (23%; lard (20.7%) and canola 
oil (2.9%)) that were (HF-D
+) or were not (HF-D
-) supplemented with vitamin D3 (2280 or 0 IU 
vitamin D3/kg). Mice that started on a vitamin D3-supplemented diet  were continued on diets 
supplemented with vitamin D3 throughout. The LF-D
- and HF-D
- were also supplemented with 2% 
calcium (vs 1% for the LF-D
+ and HF-D
+) to ensure normocalcemia. 
 
UV radiation and topical skin treatments. A bank of six 40 W lamps (Philips TL UV-B, Eindhoven, 
The Netherlands) emitting broadband UVR, 250–360 nm, with 65% of the output in the UVB range 
(280–315 nm), was used to irradiate mice to deliver sub-erythemal (1 kJ/m
2; (15)) or erythemal (4 
or 8 kJ/m
2) UVR onto clean-shaven 8 cm
2 dorsal skin as previously described (16). Alternatively, 
skin was treated with 0.1 mmoles SNAP (S-nitroso-N-acetyl-D,L-penicillamine, Sigma, (17)), a 
nitric oxide (NO) donor. In other treatments, a NO scavenger, cPTIO (Carboxy-PTIO potassium 
salt,  Sigma  (18),  0.1 mmoles),  or 1,25(OH)2D (1,25-dihydroxyvitamin D, Sigma  (19), 11.4   7 
pmoles/cm
2) were applied immediately following delivery of sub-erythemal UVR (1 kJ/m
2). This 
dose of 1,25(OH)2D was previously reported to not induce hypercalcemia (19). All topical reagents 
were diluted a vehicle consisting of ethanol, propylene glycol and water (2:1:1, (20)). All topical 
treatments were performed in the morning. 
 
Measuring weight gain. Mice were weighed weekly on the same day in the morning using a digital 
scale (Ohaus Scout, >0.1g sensitivity). Percentage weight gain was calculated from 8 weeks of age.  
 
Glucose and insulin tolerance tests.  Mice were fasted for 5 hours and then intraperitoneally 
challenged with either 1 g/kg glucose (Phebra, Lane Cove, NSW) (for glucose tolerance tests, GTT) 
or 0.5-0.75 IU/kg insulin (Lilly, Indianapolis, IN) (for insulin tolerance tests, ITT). Glucose levels 
were recorded at 0, 15, 30, 45, 60 and 90 minutes post-injection using the Accu-Chek Performa 
glucometer (Roche). 
 
Serum metabolites. Serum 25(OH)D levels were measured using IDS EIA kits (Immunodiagnostic 
Systems Ltd, Fountain Hills, AZ) as described by the manufacturer (limit of detection=5-7 nmol/L, 
CV=0.08 for internal controls).  For confirmation, 25(OH)D  levels in selected  samples  were 
measured using  a liquid chromatography-tandem mass spectrometry method (21),  which 
significantly correlated with immunoassay 25(OH)D levels (n=8;  r=0.99,  p≤0.0001).  Serum 
calcium, cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride were detected by standard 
colormetric reactions  using the Architect c16000 Analyser (Abbott Diagnostics, Abbott Park, 
USA). Glucose, insulin, adiponectin and leptin were measured in serum after fasting mice for 5 h. 
Fasting glucose was measured using the Accu-Chek  Performa glucometer (Roche, Castle Hill, 
NSW).  Fasting insulin, adiponectin and leptin were  measured using  rat/mouse insulin, mouse 
adiponectin and mouse leptin ELISA kits, respectively, as described by the manufacturer (EMD 
Millipore Corporation, Billerica MA). Serum IL-6, TNFα and IL-10 concentrations were measured   8 
in serum using ELISA as previously described (15;  22)  with antibody pairs supplied by BD 
Biosciences (Franklin Lakes, NJ, USA). The levels of detection for the IL-6, TNFα and  IL-10 
assays were 12, 3 and 14 pg/ml, respectively. Serum nitrite and nitrate was measured as previously 
described (23). 
 
Histopathological assessment of liver pathology. The severity of NAFLD was assessed by grading 
formalin-fixed and H&E-stained liver sections. Steatosis and hepatocellular ballooning were scored 
using a scoring system based on the NASH (non-alcoholic steatohepatitis) scoring system (24). A 
separate score was given for steatosis (0-3) and hepatocellular ballooning (0-3). These scores were 
added together for an overall score (≤ 6). 
 
Measurement of skin nitric oxide levels. Formation of NO in the skin was measured by a non-
invasive in vivo assay using the substrate DAF-2 (applied in the form of the membrane-permeable 
precursor  4,5-Diaminofluorescein Diacetate, DAF-2DA; Millipore, is cleaved by intracellular 
esterases to generate DAF-2; this then chemically reacts with NO to form the highly fluorescent 
compound DAF-2T; (25)). DAF-2DA (1 µmole in an ethanol, propylene glycol and water (2:1:1, 
vehicle, (20)) was applied to shaved dorsal skin for absorption for 1 h prior to skin treatment with 
UVR and/or the topical reagent. Serial images of skin fluorescence (excitation at 488 nm, emission 
at 515 nm) were taken every 5 min over 20 min using the IVIS Spectrum Bioimager (Perkin 
Elmer).  
 
Statistical analyses. Area under the curve (AUC) was calculated for GTT and ITT using GraphPad 
Prism (v5) using 0 as the baseline. Student’s t-tests and Analysis of Variance (ANOVA) were used 
to compare treatments with Tukey post-hoc analyses. Due to a significantly greater variance in 
weight gain among HFD mice, the effects of vitamin D intake and UV treatment (and their   9 
interaction) on weight gain were analysed separately to the LFD mice using SPSS (v21.0.0). Results 




Tracking the effects of chronic UVR and dietary fat on serum 25(OH)D 
 
To confirm our previous findings that UVR does not modify serum 25(OH)D in male mice (14), 
vitamin D-deficient male or female C57Bl/6 mice were exposed to a single erythemal dose (4 or 8 
kJ/m
2) of UVR, and serum 25(OH)D levels tracked over 17 days. Serum 25(OH)D levels were 
raised in a dose-related fashion by skin exposure to erythemal UVR in female but not male mice 
(Supp. Fig. 1). To determine the relative roles of dietary vitamin D and/or UVR-induced vitamin D 
in the regulation  of obesity and related cardiometabolic disease outcomes,  we performed the 
following experiment using C57Bl/6 mice (Fig. 1). Male mice were fed a vitamin D-supplemented 
or non-supplemented (low fat) diet from 4 until 8 weeks of age to establish vitamin D-sufficiency or 
-deficiency (Fig. 2A). From 8 weeks of age, mice were continued on the supplemented or non-
supplemented diets, but some were switched to a diet that was high in fat. Each of these four dietary 
treatments were further divided into three, with the shaved skin of mice chronically irradiated with 
no UVR, sub-erythemal UVR (1 kJ/m
2, biweekly) or erythemal UVR (4 kJ/m
2  fortnightly)  as 
indicated in Fig. 1. Mice were treated from 8 until 20 weeks of age with these UVR and dietary 
interventions. A high fat diet significantly increased serum 25(OH)D levels in mice fed diets not 
specifically supplemented with vitamin D (HF-D
-, LF-D
-; Fig. 2B). Mice fed either the diets further 
supplemented with vitamin D (HF-D
+, LF-D
+) had significantly greater serum 25(OH)D than those 
mice fed the diets not supplemented with vitamin D (Fig. 2B). There was no additive effect of a 
high fat diet and vitamin D supplementation on serum 25(OH)D (Fig. 2B). Although not observed 
in our preliminary (Supp. Fig. 1) and past investigations (14), chronic sub-erythemal (Fig. 2C) or 
erythemal (Fig.  2D) UVR significantly (but transiently) enhanced serum 25(OH)D, when   10 
administered to mice fed a LF-D
+ diet (but not HF-D
+, LF-D
-, or HF-D
-; see also Supp. Fig. 2). The 
effects were more pronounced for mice administered the chronic erythemal UVR, but returned to 
baseline levels after 6 weeks of UVR/dietary intervention (Fig. 2D; Supp. Fig. 2B). 
 
Chronic UVR exposure suppressed weight gain in mice fed a vitamin D-non-supplemented diet 
  
There was no effect of vitamin D supplementation on weight gain (Fig. 3A,B). Both chronic sub-
erythemal (1 kJ/m
2 biweekly) and erythemal UVR (4 kJ/m
2 fortnightly) suppressed weight gain in 
mice fed the HF-D
- (Fig. 3A) by ≥40%. Chronic erythemal UVR also suppressed weight gain in 
mice fed the LF-D
- (Fig. 3B). The effects of chronic skin exposure to UVR were less effective for 
mice fed the vitamin D-supplemented diet, where UVR suppressed weight gain in a transient 
fashion in mice fed the HF-D
+ (Suppl. Fig. 3A). At the end of the UVR/dietary intervention period 
(12 weeks), gonadal fat pad weights were not affected by dietary vitamin D supplementation but 
were significantly suppressed in mice irradiated with UVR and fed the HF-D
- (Fig. 3D). 
 
Chronic UVR exposure suppressed glucose intolerance and insulin resistance in mice fed a vitamin 
D-non-supplemented diet  
 
After 10 and 11 weeks of UVR/dietary intervention, GTTs and ITTs were performed (Table 1). 
Mice fed the high fat diets developed glucose intolerance (Supp. Fig. 3B) and insulin resistance 
(Supp. Fig. 3C), with no suppressive effect of vitamin D supplementation (Supp. Fig. 3B and 3C; 
Table 1 for AUC). Both measures were suppressed in mice chronically irradiated with UVR (either 
sub-erythemal  or erythemal)  fed the HF-D
-  (Table  1). Glucose intolerance was significantly 
suppressed by chronic sub-erythemal UVR in mice fed the HF-D
+ only (Table 1). In addition, 
fasting glucose and insulin levels were also reduced by either UVR treatment in mice fed the HF-D
-
, with fasting leptin also suppressed in mice that were chronically irradiated with erythemal UVR   11 
(Table 1). There were no effects of chronic UVR (or dietary vitamin D) on fasting adiponectin 
levels (Table 1). 
 
Chronic erythemal UVR exposure suppressed circulating cholesterol levels in mice fed a high fat 
diet not supplemented with vitamin D 
 
After 12 weeks of UVR/dietary intervention, circulating levels of triglycerides and cholesterol 
(HDL, LDL and total) were measured (Table 2). Triglyceride levels were not modified by vitamin 
D supplementation or chronic UVR (Table 2). HDL-, LDL- and total-cholesterol were suppressed 
in mice fed the HF-D
- also chronically irradiated with erythemal UVR (Table 2).  
 
Chronic UVR exposure more effectively suppressed the development of non-alcoholic fatty-liver 
disease than vitamin D supplementation 
 
The development of markers of NAFLD was measured by analysing the degree of liver steatosis 
and lobular ballooning after 12 weeks of UVR/dietary intervention (Fig. 4, Fig. 5A). Chronic skin 
exposure to UVR substantially suppressed liver histopathology in mice fed the high fat diets (Fig. 
4A-C HF-D
+; Fig. 4G-I HF-D
-; Fig. 5A) to a greater degree than achieved by dietary vitamin D 
supplementation alone (Fig. 4A HF-D
+; Fig. 4G HF-D
-; Fig. 5A). Vitamin D supplementation had 
no effect on liver weight, while chronic erythemal UVR suppressed liver weight in mice fed the 
HF-D
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Vitamin D supplementation prevented the suppressive effects of UVR upon weight gain and markers 
of MetS 
 
The results presented above suggest that many of the effects of UVR were more prominent in mice 
not further supplemented with vitamin D. We used a general linear model to assess whether there 
may be interactions within the high fat diet treatments, such that dietary vitamin D may have 
inhibited the suppressive ability of UVR. Significant interactions between dietary vitamin D and 
chronic UVR exposure were detected for weight gain (Fig. 3C; p=0.05), gonadal fatpad weights 
(Fig. 3D; p=0.03) and fasting glucose (Table 1, p=0.01), but not the other measures including liver 
histopathology (Fig. 4, Fig. 5A, p>0.05). 
 
Serum vitamin D or calcium were not related to weight loss or suppression of MetS in UVR-
irradiated mice 
 
Chronic UVR exposure suppressed aspects of weight gain and measures of MetS, independently of 
changes to circulating 25(OH)D levels (Fig. 2, Supp.  Fig.  2). Therefore it is unlikely that the 
mechanism through which UVR acted was dependent on vitamin D. As calcium levels can be 
modified by vitamin D and have been associated with weight loss (26), we also assessed circulating 
calcium levels after 12 weeks of UVR/dietary intervention, but observed no significant effects of 
dietary vitamin D or chronic skin exposure to UVR in mice fed the high fat diets (Fig. 5C). Chronic 
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Circulating TNFα was linked with improved markers of NAFLD in the absence of dietary vitamin D 
supplementation but not skin exposure to UVR 
 
The ability of phototherapy to suppress the development of NAFLD has been associated  with 
reduced expression of TNFα (13). However, chronic UVR did not modify serum TNFα levels after 
12 weeks of UVR/dietary intervention in  mice fed a high fat  diet  (Fig.  5D).  Vitamin D 
supplementation reduced circulating TNFα levels in mice fed a HF-D
+ when compared to those fed 
a HF-D
- (Fig. 5D). Serum levels of IL-6 and IL-10 were below the level of detection of the ELISA.  
 
UV-induced nitric oxide suppresses the development of obesity and symptoms of MetS   
 
A role for nitric oxide (NO), an alternate (non-vitamin D) mediator induced by UVR was examined. 
Skin levels of NO increased from as early as 5 min post-UVR/SNAP (Fig. 6A, B) treatment as 
determined using DAF-2. To examine a role for UVR-induced NO in modulating obesity and MetS 
symptoms, four week-old C57Bl/6 male mice were fed a LF-D
- for four weeks. From eight weeks 
of age, mice were either continued on this diet or switched to the HF-D
-, with HF-D
--fed mice 
further divided into five treatments, where their dorsal skin was treated with (i) vehicle only, (ii) 
sub-erythemal UVR (1 kJ/m
2) and then vehicle, (iii) SNAP, (iv) sub-erythemal UVR and then 
cPTIO or (v) sub-erythemal UVR and then 1,25(OH)2D. This final treatment was selected to test 
whether active 1,25(OH)2D could prevent the suppressive effects of UVR on obesity and MetS 
development (like dietary vitamin D in Suppl. Fig. 3A) through inhibition of skin-induced NO. 
Indeed, vitamin D may repair UV-induced DNA damage in skin by suppressing NO (27).  
 
After 12 weeks of feeding mice the HF-D
-, skin NO levels were assessed 10 min following a final 
treatment with one of the five topical treatments detailed above. Skin NO levels increased with 
UVR or SNAP (Fig. 6C).  The NO scavenger cPTIO  reduced levels of NO in skin post-UVR   14 
treatment but unexpectedly, 1,25(OH)2D did not. Serum nitrite/nitrate concentrations, measured 20 
min after the final skin treatment, were not altered by chronic low-dose UVR or SNAP (data not 
shown). Chronic UVR suppressed weight gain and the accumulation of WAT after 12 weeks of the 
HF-D
- (Fig. 6D). Chronic SNAP treatment also effectively suppressed mouse weights (although not 
weight gain) and WAT accumulation (Fig. 6D). However, neither the NO scavenger cPTIO, nor 
1,25(OH)2D reversed the suppressive effects of UVR on weight gain or WAT accumulation. Indeed 
the UVR and 1,25(OH)2D treatment was more effective than UVR alone but this observation may 
reflect  the  hypercalcemia observed  early on  with  topical 1,25(OH)2D  (4 weeks post-UVR 
(2.4±0.03) or -UVR+1,25(OH)2D  (3.5±0.07);  serum calcium,  *p<0.001). In  response to these 
observations, we halved the dose of 1,25(OH)2D administered and mice were treated only once per 
week  from 4 weeks of intervention. Despite this  change,  1,25(OH)2D-treated  mice  were  still 
modestly hypercalcemic  at the end of the experiment (12 weeks post-UVR  (2.4±0.03) or -
UVR+1,25(OH)2D (2.7±0.07); serum calcium, *p<0.001). 
 
As observed previously, chronic UVR suppressed fasting glucose, insulin and the development of 
glucose intolerance and insulin resistance (Fig. 6E, F). Here, chronic SNAP also suppressed the 
development of insulin resistance (Fig. 6F). Furthermore, cPTIO treatment following UVR reversed 
the suppressive effects of UVR alone upon fasting glucose levels (Fig. 6E). Finally, both chronic 
UVR and SNAP suppressed the development of NAFLD, while cPTIO reversed the effects of UVR 
upon liver histopathology (Fig. 6G). Cumulatively, these data suggest that UVR-induced NO may 
play an important role in modulating the development of obesity and MetS through effects on 
weight, WAT accumulation, fasting glucose, the development of insulin resistance and NAFLD.  
     15 
Discussion 
 
Here we present evidence that chronic skin exposure to low (sub-erythemal) and high (erythemal) 
dose UVR suppresses the development of obesity and measures of MetS in mice fed a high fat diet. 
Vitamin D supplementation alone  did not reproduce these effects.  In addition, the suppressive 
effects of UVR on obesity and MetS development were not observed to the same degree in mice 
that were further supplemented with vitamin D (HF-D
+).  For  mice fed a high fat  diet, serum 
25(OH)D levels were not enhanced by chronic UVR exposure, suggesting that any effects induced 
by UVR in these mice were  independent  of  circulating 25(OH)D levels.  The HF-D
-  increased 
circulating 25(OH)D; it is likely that this diet contains vitamin D, perhaps within the lard-derived 
fat fraction. Supplementation of this diet with vitamin D (i.e., the HF-D
+) further increased serum 
25(OH)D levels.  Both UV irradiation and vitamin D supplementation reduced the severity of 
NAFLD, suggesting that vitamin D can recapitulate the effects of UVR for the prevention of certain 
obesity-related pathologies. We also showed that some of the effects of UVR may occur through 
NO production. In particular, it is likely that UVR-induced NO may have profound effects on the 
development of NAFLD, as topical SNAP suppressed liver pathology, and cPTIO antagonised the 
effects of UVR. Various non-vitamin D immunomodulators induced by UVR, like NO (28), may be 
important for regulation of immunity (29) and obesity/MetS development (30). Skin exposure to 
UVR releases NO from  skin  (28)  and could  control obesity through NO-dependent  effects on 
mitochondria biogenesis within brown adipose tissue (31). We have recently shown that UVR-
induced NO reduces blood pressure in healthy human volunteers (28). NO may also be a crucial 
modulator of insulin and glucose transport, and inhibition of NO may cause insulin resistance (32). 
Combined with our results, these studies point to topically-induced NO as a potentially important 
clinical means to suppress obesity and type-2 diabetes development. 
 
The capacity of chronic UVR to suppress the development of obesity and metrics of MetS was less 
effective in mice orally supplemented with vitamin D (but not topical 1,25(OH)2D). This was an   16 
unexpected finding but could be explained by potential interactions of UVR-induced mediators and 
dietary vitamin D, including NO (27).  The different effects of dietary vitamin D and topical 
1,25(OH)2D could be accounted for by the hypercalcemia induced by chronic topical 1,25(OH)2D. 
In addition, after 12 weeks of treatment, serum 25(OH)D levels were significantly reduced by 
topical 1,25(OH)2D but not the other treatments (data not shown). Others have also observed that 
vitamin D suppressed weight gain in vivo following intraperitoneal injections of 1,25(OH)2D (5 
µg/kg every two days), although the effects on circulating calcium (and 25(OH)D) were not 
reported (33). Others have shown that UVR may increase cortisol production in skin, which has 
potential to impact the hypothalamic-pituitary-adrenal axis (34). While this might be hypothesised 
to alter physical activity, no obvious behavioural effects were observed in this study.  However, we 
cannot exclude the possibility that UVR alters neuroendocrine signalling networks in the skin (35) 
that might have systemic impact. 
 
Nakano et al showed that phototherapy suppressed NAFLD but failed to reduce obesity, steatosis 
and blood glucose levels Zucker fa-fa rats (13). These results may differ from our own through 
significant differences in the phototherapies delivered and the mouse model of obesity. Dietary 
vitamin D has also previously been shown to suppress development of NAFLD in Sprague-Dawley 
rats fed a ‘westernised’ (high fat/fructose) diet (36) and Lewis rats a choline-deficient and iron-
supplemented L-amino acid-defined (CDAA) diet (13). We also observed that dietary vitamin D 
suppressed circulating TNFα levels in mice fed a high fat diet. UVR did not suppress serum TNFα, 
suggesting that dietary vitamin D and UVR may suppress NAFLD through differing mechanisms. 
For control of NAFLD, the role of other players within the vitamin D pathway is worthy of further 
consideration.  For example, circulating levels of the vitamin D binding protein (GC) inversely 
correlate with liver steatosis, and may determine the ability of vitamin D to modulate the 
development of NAFLD (37). In addition,  1,25(OH)2D  may  act  through  the VDR  to improve 
insulin sensitivity (38).    17 
Our observations suggest that not all of the effects of UVR on disease prevention can be achieved 
through dietary vitamin D and that role of other UV-induced mediators like NO deserve further 
consideration. Furthermore, by using a mouse modelling approach we were able to remove the 
confounding effects of activity out-of-doors,  which might explain the observed associations of 
reduced obesity and increased serum 25(OH)D. A caveat is that while mice have conserved the 
ability to synthesize vitamin D and NO in the skin and systemically post-UVR, as fur-covered 
nocturnal animals they are not usually exposed to much sunlight. Further studies are required to 
translate the findings of our murine studies for humans. However, our results support recent calls 
for clinical trials that test the efficacy of skin exposure to sunlight or UVR for the control of chronic 
diseases like multiple sclerosis (39) and depression (40) that, like obesity and MetS, may take years 
to develop. In conclusion, our studies show that chronic low dose sunlight exposure may be an 
effective means of suppressing obesity and MetS in mice fed a high fat diet, through pathways that 
are independent of vitamin D and at least partially dependent on skin-derived NO.   18 
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Table 1: Area under the curve values for glucose and insulin tolerance tests (GTT, ITT) and fasting 
glucose, insulin, leptin and adiponectin levels measured 9-11 weeks post-UVR/dietary intervention. 
  






















+  0  2190±83  1200±63  9.8±0.5  8.2±3.5  36.7±3.0  10.4±0.3 
2  HF-D
+  1 kJ/m
2   1770±49**  1060±46  8.8±0.4  7.1±0.4  29.8±5.7  11.9±1.8 
3  HF-D
+  4 kJ/m
2  1880±180  1370±34  10.2±0.4  3.6±1.1  19.7±7.3  15.8±3.9 
4  LF-D
+  0  1470±67  800±38  7.9±0.3  1.0±0.4  1.5±0.6  12.9±2.8 
5  LF-D
+  1 kJ/m
2   1510±65  760±37  8.0±0.4  4.9±2.8  2.6±1.1  8.8±2.5 
6  LF-D
+  4 kJ/m
2  1390±56  770±79  7.8±0.4  1.8±1.0  2.2±0.7  11.9±1.0 
7  HF-D
-  0  2120±130  1230±15  9.8±0.3  11.1±1.9  29.8±3.5  13.0±2.6 
8  HF-D
-  1 kJ/m
2   1760±65*  1050±43*  8.7±0.3*  3.8±1.1*  32.6±5.6  11.3±0.9 
9  HF-D
-  4 kJ/m
2  1690±73*  960±72*  8.1±0.4*  3.9±2.8*  14.0±5.3*  13.0±1.1 
10  LF-D
-  0  1260±51  680±48  6.3±0.2  3.4±1.6  5.9±2.5  16.6±6.2 
11  LF-D
-  1 kJ/m
2   1280±102  600±27  6.0±0.2  1.6±1.1  1.0±0.5  10.8±0.6 
12  LF-D
-  4 kJ/m
2  1480±36  760±60  7.7±0.4  4.3±1.8  1.9±0.2  11.7±1.9 
(n=4-8 mice/treatment, *p<0.05 relative to no UVR HF-D
-; **p<0.05 relative to no UVR HF-D
+ 
with data representative of two experiments)   23 
Table  2:  Circulating triglyceride and cholesterol levels at 12 weeks post-dietary and UVR-
intervention. 
 













+  0  0.7±0.1  2.1±0.2  0.3±0.0  4.2±0.4 
2  HF-D
+  1 kJ/m
2   0.6±0.0  2.0±0.2  0.2±0.0  3.8±0.4 
3  HF-D
+  4 kJ/m
2  0.8±0.1  2.1±0.1  0.2±0.0  4.3±0.2 
4  LF-D
+  0  1.0±0.1  1.5±0.1  0.2±0.0  2.5±0.2 
5  LF-D
+  1 kJ/m
2   1.2±0.1  1.8±0.1  0.2±0.0  2.9±0.1 
6  LF-D
+  4 kJ/m
2  1.1±0.3  1.3±0.2  0.1±0.0  2.2±0.3 
7  HF-D
-  0  0.9±0.1  2.1±0.1  0.4±0.0  4.3±0.1 
8  HF-D
-  1 kJ/m
2   0.6±0.0  2.1±0.0  0.3±0.0  4.2±0.2 
9  HF-D
-  4 kJ/m
2  0.9±0.1  1.5±0.2*  0.2±0.0*  2.6±0.3* 
10  LF-D
-  0  1.2±0.1  1.6±0.3  0.1±0.0  2.4±0.4 
11  LF-D
-  1 kJ/m
2   0.9±0.1  1.4±0.1  0.1±0.0  2.0±0.1 
12  LF-D
-  4 kJ/m
2  1.1±0.1  1.5±0.1  0.1±0.0  2.3±0.1 
(n=4 mice/treatment, *p<0.05 relative to no UVR HF-D
-  with data a representative of two 
experiments)     24 
Figure legends 
Supplementary Figure 1: Erythemal UVR increased serum 25(OH)D levels in initially vitamin D-
deficient  female but not male mice.  Four week-old  C57Bl/6  mice were fed a low fat diet not 
supplemented with vitamin D for four weeks to reduce serum 25(OH)D levels to less than 20 
nmol.L
-1 (dotted line). Serum 25(OH)D levels were measured following the exposure of the shaved 
dorsal skin of the initially vitamin D-deficient mice to 4 or 8 kJ/m
2 UVR. Data is shown as mean ± 
SEM (n=4-8 mice/treatment/time point, *p<0.05 relative to initial serum 25(OH)D levels). 
 
Figure 1: The experimental approach. Four week-old C57Bl/6 male mice were fed a low fat diet 
supplemented with vitamin D (LF-D
+) or not (LF-D
-) for four weeks. At eight weeks of age, mice 
were either continued on these diets or switched to a diet that was high in fat and supplemented 
(HF-D
+) or not (HF-D
-) with vitamin D. At the same time, each dietary group was further divided 
into three treatments of mice that were chronically irradiated with sub-erythemal UVR (biweekly, 1 
kJ/m
2), erythemal UVR (fortnightly, 4 kJ/m
2) or no UVR. Mice were fed these diets and irradiated 
with these UVR regimens for a further 12 weeks until mice were twenty weeks of age. There were a 
total of 12 treatments, with 18 mice per treatment. The experiment was performed two times. 
 
Figure 2: The effects of chronic skin exposure to UVR, dietary vitamin D and a high fat diet on 
serum 25(OH)D. In (A), four week-old C57Bl/6 male mice were fed a low fat diet supplemented 
with vitamin D (LF-D
+) or not (LF-D
-) for four weeks. At eight weeks of age (week 0 for Fig. 2B – 
D), mice were either continued on these diets or switched to a diet that was high in fat and 
supplemented (HF-D
+) or not (HF-D
-) with vitamin D. At the same time, each dietary group was 
further divided into three treatments of mice that were chronically irradiated with (B) no UVR, (C) 
sub-erythemal UVR (biweekly, 1 kJ/m
2), or (D) erythemal UVR (fortnightly, 4 kJ/m
2) for a further 
12 weeks.  In (B) –  (D), serum 25(OH)D levels are depicted for mice  that underwent these   25 
UVR/dietary interventions for 12 weeks. Data are shown as mean ± SEM for n=4-9 mice at each 
time, pooled from two independent experiments (*p<0.05). 
 
Supplementary Figure 2: The effects of chronic skin exposure to UVR, dietary vitamin D and a high 
fat diet on serum 25(OH)D. Data from Figure 2 are shown in an alternate fashion, comparing the 
effects of no UVR, or, chronic skin exposure to sub-erythemal  UVR (biweekly, 1 kJ/m
2) or 
erythemal UVR (fortnightly, 4 kJ/m
2) on serum levels of 25(OH)D for mice fed a (A) high (HF-D
+) 
or (B) low fat (LF-D
+) diet supplemented with vitamin D, or, (C) high (HF-D
-) or (D) low fat (LF-
D
-) diet not supplemented with vitamin D. Data are shown as mean ± SEM for n=4-9 mice at each 
time, pooled from two independent experiments (*p<0.05). 
 
Figure 3: Chronic UVR suppressed weight gain in mice fed high or low fat diets not supplemented 
with vitamin D. Four week-old C57Bl/6 male mice were fed a low fat diet supplemented with 
vitamin D (LF-D
+) or not (LF-D
-) with vitamin D for four weeks. At eight weeks of age (week 0 for 
Fig. 3A – B), mice were either continued on these diets or switched to a diet that was high in fat and 
supplemented (HF-D
+) or not (HF-D
-) with vitamin D. At the same time, each dietary group was 
further divided into three treatments of mice that were chronically irradiated with no UVR, sub-
erythemal UVR (biweekly, 1 kJ/m
2),  or  erythemal UVR (fortnightly, 4  kJ/m
2). In (A)  –  (B), 
percentage weight gain is shown for mice that underwent these UVR/dietary interventions for 12 
weeks (until 20 weeks of age) for mice fed a (A) high fat or (B) low fat diet. Data are shown as 
mean ± SEM for n=18 mice/treatment from a representative of two independent experiments. In (C) 
total weight gain after 12 weeks of these UVR/dietary interventions (at 20 weeks of age) is shown 
for all treatments (mean + SEM). In (D), after 12 weeks of these UVR/dietary interventions (at 20 
weeks of age) gonadal fatpad (n=18/treatment) weights were measured. Data are representative of 
two independent experiments (mean + SEM) *p<0.05). 
   26 
Supplementary Figure 3: Dietary vitamin D did  not affect weight gain or the development of 
glucose tolerance or insulin resistance for mice fed a high or low fat diet. Four week-old C57Bl/6 
male mice were fed a low fat diet supplemented with vitamin D (LF-D
+) or not (LF-D
-) for four 
weeks. At eight weeks of age (week 0 for Suppl. Fig. 3A), mice were either continued on these diets 
or switched to a diet that was high in fat and supplemented (HF-D
+) or not (HF-D
-) with vitamin D. 
At the same time, each dietary group was further divided into three treatments of mice that were 
chronically irradiated with no UVR, sub-erythemal UVR (biweekly, 1 kJ/m
2), or erythemal UVR 
(fortnightly, 4 kJ/m
2) for 12 weeks until 20 weeks of age. In (A), percentage weight gain is shown 
(n=18 mice/treatment)  for mice fed the HF-D
+  or LF-D
+. In (B), a glucose tolerance test was 
performed after 10 weeks of the UVR/dietary interventions  (at 18 weeks of age, n=8 
mice/treatment), with data shown for non-irradiated mice. In (C), an insulin tolerance test was 
performed after 11 weeks of  the UVR/dietary interventions  (at 19 weeks of age, n=8 
mice/treatment) with data shown for non-irradiated mice. Data are shown as mean ± SEM from a 
representative of two independent experiments (*p<0.05). 
 
Figure 4: Chronic UVR significantly reduced the extent of liver steatosis and lobular ballooning in 
mice fed a high fat diet. Four week-old C57Bl/6 male mice were fed a low fat diet supplemented 
with vitamin D (LF-D
+) or not (LF-D
-) for four weeks. At eight weeks of age, mice were either 
continued on these diets or switched to a diet that was high in fat and supplemented (HF-D
+) or not 
(HF-D
-) with vitamin D. At the same time, each dietary group was further divided into three 
treatments of mice that were chronically irradiated with no UVR (A, D, G, J), sub-erythemal UVR 
(biweekly, 1 kJ/m
2; B, E, H, K), or erythemal UVR (fortnightly, 4 kJ/m
2; C, F, I, L). After 12 weeks 
of these UVR/dietary interventions (at 20 weeks of age), the extent of liver histopathology was 
measured in liver specimens (n=10/treatment for data pooled from two independent experiments). 
Shown in A-L are representative H&E-stained sections of liver for each treatment   27 
(20xmagnification with the scales in B and C equivalent to 150 µm). Examples of liver steatosis  
(blue arrow) and lobular ballooning (red arrow) are shown in section (G). 
 
Figure 5: Chronic UVR significantly reduced the extent of liver histopathology in mice fed a high 
fat diet. Four week-old C57Bl/6 male mice were fed a low fat diet supplemented with vitamin D 
(LF-D
+) or not (LF-D
-) for four weeks. At eight weeks of age, mice were either continued on these 
diets or switched to a diet that was high in fat and supplemented (HF-D
+) or not (HF-D
-) with 
vitamin D. At the same time, each dietary group was further divided into three treatments of mice 
that were chronically irradiated with no UVR, sub-erythemal UVR (biweekly, 1 kJ/m
2), or 
erythemal UVR (fortnightly, 4 kJ/m
2). After 12 weeks of these UVR/dietary interventions (at 20 
weeks of age), the (A) extent of liver histopathology (n=10/treatment for data pooled from two 
independent experiments),  (B) liver weights (n=18/treatment  for data from a representative 
experiment) and serum levels serum levels of (C) calcium (n=4-8/treatment for data pooled from 
two independent  experiments)  and  (D)  TNFα  (n=12-18/treatment for data pooled from two 
independent experiments) are shown. Data are shown as mean + SEM (*p<0.05). 
 
Figure 6: The UVR-induced mediator, nitric oxide may regulate body weight, WAT accumulation, 
glucose metabolism and the development of NAFLD in mice fed a high fat diet. In (A) and (B), 
using the DAF-2DA substrate, skin nitric oxide levels are shown for adult C57Bl/6 male mice fed a 
low fat diet not supplemented with vitamin D (LF-D
-), 5 min following skin treatment with vehicle, 
1 kJ/m
2 UVR or the nitric oxide donor, SNAP; with a quantitative measure (photons/sec) shown in 
(A) and representative skin fluorescence shown in (B). Four week-old C57Bl/6 male mice were fed 
a LF-D
-  for four weeks. At eight weeks of age, mice were either continued on these diets or 
switched to a diet that was high in fat, not supplemented with vitamin D (HF-D
-). Within the HF-D
- 
treatments, mice were further divided into five treatments. The shaved dorsal skin of these mice 
were; (i) treated with vehicle only, (ii) chronically irradiated with sub-erythemal UVR (biweekly, 1   28 
kJ/m
2) and then vehicle, (iii) topically treated with SNAP, (iv) chronically irradiated with sub-
erythemal UVR and then cPTIO or (v) chronically irradiated with sub-erythemal UVR and then 
1,25(OH)2D. Mice were treated for 12 weeks with these skin/dietary interventions until 20 weeks of 
age. In (C), skin NO levels, 10 min post-skin treatment (n=8 mice/treatment);  in (D), mouse 
weights, weight gain and WAT (WAT) weights (n=18 mice/treatment); in (E), fasting glucose and 
GTT AUC (area under the curve, n=8 mice/treatment); in (F), fasting insulin and ITT AUC (n=8 
mice/treatment; and in (G), liver histopathology scores (n=8 mice/treatment). Data are shown as 
mean + SEM from one experiment (*p<0.05).  Figure 1 
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